当前位置: X-MOL 学术Expert Rev. Pharmacoecon. Outcomes Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.
Expert Review of Pharmacoeconomics & Outcomes Research ( IF 1.8 ) Pub Date : 2020-09-23 , DOI: 10.1080/14737167.2020.1807331
Ziyi Lin 1 , Jianwei Xuan 1
Affiliation  

ABSTRACT

Background

Orally disintegrating tablet (ODT) formulation of antipsychotics is one of the innovative drug delivery systems developed to improve medication adherence. We aimed to evaluate the cost-effectiveness of aripiprazole ODT vs. aripiprazole standard oral tablet (SOT), as well as olanzapine SOT in China.

Methods

We developed a discrete event simulation model from government payers’ perspective. On the entry, 100,000 patients in each group were simulated for relapse, adverse events, changing adherence level, medication discontinuation, switching or quitting in response to three different medication adherence levels. The model projected quality adjusted life years (QALYs) and treatment costs over a 1-year time horizon. Parameter uncertainties were assessed through sensitivity analyses.

Results

The QALYs per patient over 1-year treatment with aripiprazole ODT, aripiprazole SOT, or olanzapine SOT, were 0.7282, 0.7112, and 0.7218, respectively. The corresponding costs were $1,423, $2,215, and $1,493. In both comparisons, aripiprazole ODT was dominant. Compared with aripiprazole SOT and olanzapine SOT, the likelihood of aripiprazole ODT being cost-effective was 99.2% and 69.2%, respectively, using 3 times per capita GDP per QALY as willingness-to-pay threshold.

Conclusions

The aripiprazole ODT is associated with more QALYs at lower costs compared with both aripiprazole SOT and olanzapine SOT in treating schizophrenia in China.

更新日期:2020-10-15
down
wechat
bug